4.6 Article

Transdifferentiation of human fibroblasts into hepatocyte-like cells by defined transcriptional factors

Journal

HEPATOLOGY INTERNATIONAL
Volume 7, Issue 3, Pages 937-944

Publisher

SPRINGER
DOI: 10.1007/s12072-013-9432-5

Keywords

Transdifferentiation; FOXA2; HNF4 alpha; C/EBP beta; Transcription factors

Funding

  1. Nakayama Cancer Research Institute Scholarship
  2. Itoe Okamoto Scholarship Grant
  3. Hisako Yamakawa Award at Tokyo Women's Medical University

Ask authors/readers for more resources

Liver transplantation is currently the only curative therapeutic option for end-stage liver cirrhosis. However, due to the limitations of donor liver availability and occasional rejection, it cannot always be successfully applied. In this study, we determined whether fibroblasts can be transdifferentiated into hepatocyte-like cells by transcription factors that initiate and maintain hepatocyte differentiation. Fibroblasts were transduced with retrovirus vectors carrying FOXA2, HNF4 alpha, and C/EBP beta. To enhance the efficiency of transdifferentiation, cMyc was also expressed. Transdifferentiation was successful using both neonatal fibroblasts and human forehead fibroblasts. The transdifferentiated cells produced hepatocyte-specific proteins such as albumin and cytochrome, and had important hepatocyte-specific functions, such as glycogen storage and indocyanine green uptake, suggesting that the cells function at least as partial hepatocytes. These results provide a novel method of generating differentiated hepatocyte-like cells, and may represent an alternative source of cells for future cell-based therapeutics for end-stage liver diseases.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Genetics & Heredity

Aberrant expression of a novel circular RNA in pancreatic cancer

Takahiro Seimiya, Motoyuki Otsuka, Takuma Iwata, Eri Tanaka, Kazuma Sekiba, Chikako Shibata, Masaru Moriyama, Ryo Nakagawa, Reo Maruyama, Kazuhiko Koike

Summary: A large-scale circRNA profiling analysis was conducted in PDAC tissues using circular RNA-specific RNA sequencing, identifying over 40,000 previously unknown circRNAs, some of which were upregulated in PDAC tissues. A novel circRNA, named circPDAC RNA, was found to be upregulated in PDAC but not expressed in normal human cells, serving as a potential biomarker for cancers including PDAC.

JOURNAL OF HUMAN GENETICS (2021)

Article Gastroenterology & Hepatology

Post-treatment cell-free DNA as a predictive biomarker in molecular-targeted therapy of hepatocellular carcinoma

Takuma Nakatsuka, Hayato Nakagawa, Yuki Hayata, Taijiro Wake, Tomoharu Yamada, Mizuki Nishibatake Kinoshita, Ryo Nakagomi, Masaya Sato, Tatsuya Minami, Koji Uchino, Kenichiro Enooku, Yotaro Kudo, Yasuo Tanaka, Takahiro Kishikawa, Motoyuki Otsuka, Ryosuke Tateishi, Kazuhiko Koike

Summary: This study found that plasma cfDNA levels in HCC patients were associated with clinical stage and high levels were linked to poor prognosis. Post-treatment increase in cfDNA levels was correlated with response to MTAs, and targeted ultra-deep sequencing of post-treatment cfDNA successfully detected various gene mutations, showing promise in predicting treatment effects.

JOURNAL OF GASTROENTEROLOGY (2021)

Article Biotechnology & Applied Microbiology

Mutant KRAS drives metabolic reprogramming and autophagic flux in premalignant pancreatic cells

Tatsunori Suzuki, Takahiro Kishikawa, Tatsuyuki Sato, Norihiko Takeda, Yuki Sugiura, Takahiro Seimiya, Kazuma Sekiba, Motoko Ohno, Takuma Iwata, Rei Ishibashi, Motoyuki Otsuka, Kazuhiko Koike

Summary: Mutational activation of the KRAS gene is an early event in the carcinogenesis of almost all PDAC. Research shows that KRAS mutation increases the dependency on glucose and glutamine and reduces intracellular levels of amino acids, necessitating higher autophagic flux for cell viability.

CANCER GENE THERAPY (2022)

Review Gastroenterology & Hepatology

Potential of HBx Gene for Hepatocarcinogenesis in Noncirrhotic Liver

Kazuma Sekiba, Motoyuki Otsuka, Kazuhiko Koike

Summary: Current treatments for hepatitis B virus using nucleos(t)ide analogs cannot eliminate the risk of hepatocellular carcinoma development. HBV-associated HCC can develop even in the absence of liver cirrhosis, suggesting that HBV possesses direct oncogenic potential. Multiple molecules and pathways are involved in HBx-associated HCC development, indicating that the mechanisms underlying HBx-mediated hepatocarcinogenesis are still unclear.

SEMINARS IN LIVER DISEASE (2021)

Article Gastroenterology & Hepatology

Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020

Katsutoshi Tokushige, Kenichi Ikejima, Masafumi Ono, Yuichiro Eguchi, Yoshihiro Kamada, Yoshito Itoh, Norio Akuta, Masato Yoneda, Motoh Iwasa, Masashi Yoneda, Motoyuki Otsuka, Nobuharu Tamaki, Tomomi Kogiso, Hiroto Miwa, Kazuaki Chayama, Nobuyuki Enomoto, Tooru Shimosegawa, Tetsuo Takehara, Kazuhiko Koike

Summary: NAFLD and NASH have become significant public health issues in both Western countries and Japan, with hepatic fibrosis being a key prognostic factor. Effective screening methods for NAFLD and urgent surveillance for HCC are necessary in Japan, where non-viral liver disease-related HCC cases are on the rise. Cardiovascular disease is the leading cause of death in NAFLD patients, emphasizing the importance of CVD monitoring in clinical practice. Several drug trials are ongoing for NAFLD/NASH therapy, with new treatments like SGLT2 inhibitors and GLP-1 analogues showing promise for future interventions.

HEPATOLOGY RESEARCH (2021)

Review Gastroenterology & Hepatology

Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020

Katsutoshi Tokushige, Kenichi Ikejima, Masafumi Ono, Yuichiro Eguchi, Yoshihiro Kamada, Yoshito Itoh, Norio Akuta, Masato Yoneda, Motoh Iwasa, Masashi Yoneda, Motoyuki Otsuka, Nobuharu Tamaki, Tomomi Kogiso, Hiroto Miwa, Kazuaki Chayama, Nobuyuki Enomoto, Tooru Shimosegawa, Tetsuo Takehara, Kazuhiko Koike

Summary: Nonalcoholic fatty liver disease (NAFLD) is a serious public health issue in Japan, with nonalcoholic steatohepatitis (NASH) being a progressive form that can lead to liver cirrhosis and increase the risk of hepatocellular carcinoma. The most common cause of death in NAFLD patients is cardiovascular disease.

JOURNAL OF GASTROENTEROLOGY (2021)

Article Gastroenterology & Hepatology

HBx-induced degradation of Smc5/6 complex impairs homologous recombination-mediated repair of damaged DNA

Kazuma Sekiba, Motoyuki Otsuka, Kazuyoshi Funato, Yu Miyakawa, Eri Tanaka, Takahiro Seimiya, Mari Yamagami, Takeya Tsutsumi, Kazuya Okushin, Kei Miyakawa, Akihide Ryo, Kazuhiko Koike

Summary: The HBV X protein degrades the Smc5/6 complex, impairing DNA double-strand break repair and promoting cellular transformation. Nitazoxanide (NTZ) restores the function of the Smc5/6 complex, repairing HR in HBx-expressing cells and promoting colony formation.

JOURNAL OF HEPATOLOGY (2022)

Article Oncology

Impact of Obesity and Heavy Alcohol Consumption on Hepatocellular Carcinoma Development after HCV Eradication with Antivirals

Tatsuya Minami, Ryosuke Tateishi, Naoto Fujiwara, Ryo Nakagomi, Takuma Nakatsuka, Masaya Sato, Koji Uchino, Kenichiro Enooku, Hayato Nakagawa, Hidetaka Fujinaga, Masashi Izumiya, Kazuyuki Hanajiri, Yoshinari Asaoka, Yuji Kondo, Yasuo Tanaka, Motoyuki Otsuka, Takamasa Ohki, Masahiro Arai, Atsushi Tanaka, Kiyomi Yasuda, Hideaki Miura, Itsuro Ogata, Toshiro Kamoshida, Kazuaki Inoue, Yukihiro Koike, Masatoshi Akamatsu, Hiroshi Mitsui, Hajime Fujie, Keiji Ogura, Hideo Yoshida, Tomonori Wada, Kiyohiko Kurai, Hisato Maekawa, Shuntaro Obi, Takuma Teratani, Naohiko Masaki, Kayo Nagashima, Takashi Ishikawa, Naoya Kato, Kyoji Moriya, Hiroshi Yotsuyanagi, Kazuhiko Koike

Summary: Obesity and heavy alcohol consumption are independent risk factors for the development of hepatocellular carcinoma in patients after achieving sustained virological response with antiviral therapy.

LIVER CANCER (2021)

Article Gastroenterology & Hepatology

MNX1-HNF1B Axis Is Indispensable for Intraductal Papillary Mucinous Neoplasm Lineages

Hiroyuki Kato, Keisuke Tateishi, Hiroaki Fujiwara, Takuma Nakatsuka, Keisuke Yamamoto, Yotaro Kudo, Yoku Hayakawa, Hayato Nakagawa, Yasuo Tanaka, Hideaki Ijichi, Motoyuki Otsuka, Dosuke Iwadate, Hiroki Oyama, Sachiko Kanai, Kensaku Noguchi, Tatsunori Suzuki, Tatsuya Sato, Ryunosuke Hakuta, Kazunaga Ishigaki, Kei Saito, Tomotaka Saito, Naminatsu Takahara, Takahiro Kishikawa, Tsuyoshi Hamada, Ryota Takahashi, Koji Miyabayashi, Suguru Mizuno, Hirofumi Kogure, Yousuke Nakai, Yoshihiro Hirata, Atsushi Toyoda, Kazuki Ichikawa, Wei Qu, Shinichi Morishita, Junichi Arita, Mariko Tanaka, Tetsuo Ushiku, Kiyoshi Hasegawa, Mitsuhiro Fujishiro, Kazuhiko Koike

Summary: Our study identified the MNX1-HNF1B axis to be biologically significant in IPMN lineages, and this axis is crucial for the regulation of genes such as MYC, SOX9, and OLFM4.

GASTROENTEROLOGY (2022)

Article Biochemistry & Molecular Biology

Hepatitis B virus-associated hepatocellular carcinoma with Smc5/6 complex deficiency is susceptible to PARP inhibitors

Kazuyoshi Funato, Motoyuki Otsuka, Kazuma Sekiba, Yu Miyakawa, Takahiro Seimiya, Chikako Shibata, Takahiro Kishikawa, Mitsuhiro Fujishiro

Summary: DNA repair processes are potential therapeutic targets for cancer treatment. This study reveals that HBV-associated HCC with a deficiency in the Smc5/6 complex is more susceptible to PARP inhibitors due to impaired homologous recombination. The findings suggest a potential treatment strategy for HBV-related HCC.

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2022)

Article Biochemistry & Molecular Biology

The RNA-Binding Protein ELAVL1 Regulates Hepatitis B Virus Replication and Growth of Hepatocellular Carcinoma Cells

Hiroaki Kanzaki, Tetsuhiro Chiba, Tatsuya Kaneko, Junjie Ao, Motoyasu Kan, Ryosuke Muroyama, Shingo Nakamoto, Tatsuo Kanda, Hitoshi Maruyama, Jun Kato, Yoh Zen, Ai Kotani, Kazuma Sekiba, Motoyuki Otsuka, Masayuki Ohtsuka, Naoya Kato

Summary: ELAVL1 protein is not only involved in the replication of hepatitis B virus, but also has an impact on the cell growth of hepatocellular carcinoma, making it a potential therapeutic target for HBV-related HCC treatment.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

Article Oncology

Lipolysis by pancreatic cancer-derived extracellular vesicles in cancer-associated cachexia via specific integrins

Chikako Shibata, Motoyuki Otsuka, Takahiro Seimiya, Takahiro Kishikawa, Kazunaga Ishigaki, Mitsuhiro Fujishiro

CLINICAL AND TRANSLATIONAL MEDICINE (2022)

Letter Medicine, General & Internal

Circulating Tumor DNA Guiding Adjuvant Therapy in Colon Cancer

Elif Hindie

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Letter Medicine, General & Internal

Circulating Tumor DNA Guiding Adjuvant Therapy in Colon Cancer

Motoyuki Otsuka

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Article Medicine, Research & Experimental

WWP1 inactivation enhances efficacy of PI3K inhibitors while suppressing their toxicities in breast cancer models

Takahiro Kishikawa, Hiroshi Higuchi, Limei Wang, Nivedita Panch, Valerie Maymi, Sachem Best, Samuel Lee, Genso Notoya, Alex Toker, Lydia E. Matesic, Gerburg M. Wulf, Wenyi Wei, Motoyuki Otsuka, Kazuhiko Koike, John G. Clohessy, Yu-Ru Lee, Pier Paolo Pandolfi

Summary: Activation of the PI3K signaling pathway in tumorigenesis is linked to PTEN inactivation, with WWP1 playing a role in PTEN dissociation from the plasma membrane and activation of PI3K signaling. Inhibition of WWP1 synergizes with PI3K inhibitors to suppress tumor growth and reduce hyperglycemia and insulin feedback, enhancing the therapeutic potential of PI3K inhibitors and opening new avenues for combination cancer therapy.

JOURNAL OF CLINICAL INVESTIGATION (2021)

No Data Available